RapidPulse Raises $48M in Series B Funding to Advance Stroke Treatment Technology
Top Picks
Stay Ahead of the Market
Get the latest startup funding, hiring trends and global opportunities delivered to your inbox every week.
RapidPulse, a Miami-based medical technology company, has raised $48 million in a Series B funding round to advance the development of its aspiration technology for treating acute ischemic stroke.
Medtronic and Existing Investors Back the Round
The funding round was led by Medtronic, TechWald Next S.p.A., and S3 Ventures.
New investors SBI Investment Company Ltd. and Florida Opportunity Fund also participated. They joined existing backers Santé Ventures, Syntheon, Hatteras Venture Partners, and Epidarex Capital.
Funding to Support Clinical Study and Product Development
RapidPulse plans to use the new capital to complete its ongoing investigational device exemption (IDE) study, Thrombectomy Using Pulsed Aspiration for Reperfusion of Brain Occlusions (TURBO).
In addition, the company will expand its proprietary technology platform. The expansion includes developing a broader range of catheter sizes designed for different clinical needs.
Developing Aspiration Technology for Stroke Care
Led by CEO Sean McBrayer, RapidPulse develops medical devices focused on treating acute ischemic stroke.
The company's technology uses a controlled cyclic aspiration method that aims to improve clot engagement and removal during thrombectomy procedures.
At present, the TURBO study is underway in the United States and Europe. The clinical evaluation is intended to support the company's regulatory pathway in the U.S.
Recently funded and expanding your team?
WorkNation helps startups and growth-stage companies hire top talent faster.
📩 hiring@worknation.buzz | 🌐 worknation.buzz/hiring-solutions
